Nonsense-mediated MRNA Decay Inhibition Synergizes with MDM2 Inhibition to Suppress TP53 Wild-type Cancer Cells in P53 Isoform-dependent Manner

Overview

Journal Cell Death Discov

Date 2022 Sep 30

PMID 36180435

Authors

Ying Li

Meng Wu

Lili Zhang

Li Wan

Hexin Li

Lanxin Zhang

Gaoyuan Sun

Wei Huang

Junhua Zhang

Fei Su

Min Tang

Fei Xiao

Affiliations

Soon will be listed here.

Abstract

The restoration of the normal function of the tumour suppressors, such as p53, is an important strategy in tumour therapeutics. Nonsense-mediated mRNA decay (NMD) inhibition by NMD inhibitor (NMDi) upregulates functional p53 isoforms, p53β and p53γ, and activates the p53 pathway. XR-2, a novel mouse double minute 2 homolog (MDM2) inhibitor, can disrupt the interaction between p53 and MDM2, thus decreasing the MDM2-mediated degradation of p53 and increasing the p53 protein levels. However, the combined effects of these two agents have not been thoroughly explored. This study combined XR-2 and NMDi in four TP53 wild-types and four TP53-mutated cancer cell lines. The combination of these two agents achieved significant synergistic effects on TP53 wild-type cancer cell lines by transactivating p53 target genes, inducing apoptosis, cell-cycle arrest and DNA damage repair. The p53β isoform induced by NMDi enhances the transactivation ability of p53α induced by XR-2, which partially explains the mechanism of the synergistic effects of XR-2 and NMDi. This study identified a combination treatment of NMDi and XR-2 which could serve as a novel cancer therapeutic approach for MDM2-overexpressed TP53 wild-type cancers and delineated a future therapy based on the further reactivation of p53.

Citing Articles

Re-appraising the evidence for the source, regulation and function of p53-family isoforms.

Lopez I, Valdivia I, Vojtesek B, Fahraeus R, Coates P Nucleic Acids Res. 2024; 52(20):12112-12129.

PMID: 39404067 PMC: 11551734. DOI: 10.1093/nar/gkae855.

SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA.

Yu S, Si Y, Yu J, Jiang C, Cheng F, Xu M Cancer Sci. 2024; 115(12):3915-3927.

PMID: 39329452 PMC: 11611762. DOI: 10.1111/cas.16356.

Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.

Parodis I, Lindblom J, Barturen G, Ortega-Castro R, Cervera R, Pers J Ann Rheum Dis. 2024; 83(7):889-900.

PMID: 38373843 PMC: 11187369. DOI: 10.1136/ard-2023-224795.

Synthesis and Antineoplastic Activity of a Dimer, Spiroindolinone Pyrrolidinecarboxamide.

Cui J, Wang Y, Li X, Xiao F, Ren H, Wu M Molecules. 2023; 28(9).

PMID: 37175323 PMC: 10180320. DOI: 10.3390/molecules28093912.

High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Wang X, Li W, Lou N, Han W, Hai B, Xiao W Pharmgenomics Pers Med. 2023; 16:1-14.

PMID: 36636625 PMC: 9831534. DOI: 10.2147/PGPM.S382843.

References

Ferguson M, Gerak C, Chow C, Rastelli E, Elmore K, Stahl F . The antimalarial drug mefloquine enhances TP53 premature termination codon readthrough by aminoglycoside G418. PLoS One. 2019; 14(5):e0216423. PMC: 6532957. DOI: 10.1371/journal.pone.0216423. View

Sharma J, Du M, Wong E, Mutyam V, Li Y, Chen J . A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat Commun. 2021; 12(1):4358. PMC: 8285393. DOI: 10.1038/s41467-021-24575-x. View

Lindeboom R, Vermeulen M, Lehner B, Supek F . The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nat Genet. 2019; 51(11):1645-1651. PMC: 6858879. DOI: 10.1038/s41588-019-0517-5. View

Bourdon J, Khoury M, Diot A, Baker L, Fernandes K, Aoubala M . p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res. 2011; 13(1):R7. PMC: 3109573. DOI: 10.1186/bcr2811. View

Karam R, Carvalho J, Bruno I, Graziadio C, Senz J, Huntsman D . The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. Oncogene. 2008; 27(30):4255-60. DOI: 10.1038/onc.2008.62. View

Supek F, Lehner B, Lindeboom R . To NMD or Not To NMD: Nonsense-Mediated mRNA Decay in Cancer and Other Genetic Diseases. Trends Genet. 2020; 37(7):657-668. DOI: 10.1016/j.tig.2020.11.002. View

Yi Z, Sanjeev M, Singh G . The Branched Nature of the Nonsense-Mediated mRNA Decay Pathway. Trends Genet. 2020; 37(2):143-159. PMC: 7854845. DOI: 10.1016/j.tig.2020.08.010. View

Silden E, Hjelle S, Wergeland L, Sulen A, Andresen V, Bourdon J . Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines. PLoS One. 2013; 8(2):e56276. PMC: 3569410. DOI: 10.1371/journal.pone.0056276. View

Popp M, Maquat L . Nonsense-mediated mRNA Decay and Cancer. Curr Opin Genet Dev. 2017; 48:44-50. PMC: 5869107. DOI: 10.1016/j.gde.2017.10.007. View

10.

Doma M, Parker R . RNA quality control in eukaryotes. Cell. 2007; 131(4):660-8. DOI: 10.1016/j.cell.2007.10.041. View

11.

Khoury M, Bourdon J . The isoforms of the p53 protein. Cold Spring Harb Perspect Biol. 2010; 2(3):a000927. PMC: 2829963. DOI: 10.1101/cshperspect.a000927. View

12.

Demir O, Barros E, Offutt T, Rosenfeld M, Amaro R . An integrated view of p53 dynamics, function, and reactivation. Curr Opin Struct Biol. 2021; 67:187-194. PMC: 8985518. DOI: 10.1016/j.sbi.2020.11.005. View

13.

Kurosaki T, Popp M, Maquat L . Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat Rev Mol Cell Biol. 2019; 20(7):406-420. PMC: 6855384. DOI: 10.1038/s41580-019-0126-2. View

14.

Haupt Y, Maya R, Kazaz A, Oren M . Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630):296-9. DOI: 10.1038/387296a0. View

15.

Sancar A, Lindsey-Boltz L, Unsal-Kacmaz K, Linn S . Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004; 73:39-85. DOI: 10.1146/annurev.biochem.73.011303.073723. View

16.

Oliner J, Saiki A, Caenepeel S . The Role of MDM2 Amplification and Overexpression in Tumorigenesis. Cold Spring Harb Perspect Med. 2016; 6(6). PMC: 4888815. DOI: 10.1101/cshperspect.a026336. View

17.

Gupta A, Shah K, Oza M, Behl T . Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomed Pharmacother. 2018; 109:484-492. DOI: 10.1016/j.biopha.2018.10.155. View

18.

Wu M, Cui J, Hou H, Li Y, Liu S, Wan L . Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer. Front Pharmacol. 2022; 13:871259. PMC: 9081362. DOI: 10.3389/fphar.2022.871259. View

19.

Anczukow O, Ware M, Buisson M, Zetoune A, Stoppa-Lyonnet D, Sinilnikova O . Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?. Hum Mutat. 2007; 29(1):65-73. DOI: 10.1002/humu.20590. View

20.

Marcel V, Fernandes K, Terrier O, Lane D, Bourdon J . Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ. 2014; 21(9):1377-87. PMC: 4131182. DOI: 10.1038/cdd.2014.73. View